skip to main content

Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.

Elanco to Acquire Boehringer Ingelheim Vetmedica’s Vaccines Portfolio

As reported in The Wall Street Journal, Bloomberg, Reuters and other media outlets, Paul, Weiss client Elanco U.S., Inc., a subsidiary of Paul, Weiss client Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine and rabies vaccines portfolio, as well as a fully integrated manufacturing and R&D site, for $885 million. The transaction is expected to close by early 2017.

The Paul, Weiss team included litigation partners Andrew Forman and Rick Rule.

October 5, 2016

© 2020 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy